Jacob Van Naarden
CIK 1661254 · EVP,Pres LLY Oncology&HdCorpBD · last filed 2026-02-11
Jacob Van Naarden is an EVP,Pres LLY Oncology&HdCorpBD who has filed 35 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing shows the insider was granted $5.1M of LLY on Feb 11, 2026. Across all open-market trades the lifetime net is −$11.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $36.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$36.17M
2
35
-$11.12M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LLY | EVP,Pres LLY Oncology&HdCorpBD | 31,928 | $1133.00 | $36.17M | $647.4K | 12 | 2026-02-11 |
| Loxo Oncology, Inc. (LOXO) Delisted | Chief Operating Officer | 0 | — | — | -$11.77M | 23 | 2019-02-15 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-11 | LLY | Grant (A) | +4,865 | $5.08M | EDGAR |
| 2026-02-03 | LLY | Mixed | +2,198 | -$1.98M | EDGAR |
| 2025-08-13 | LLY | Buy (P) | +1,000 | $647.4K | EDGAR |
| 2025-02-12 | LLY | Grant (A) | +6,103 | $5.30M | EDGAR |
| 2025-02-04 | LLY | Mixed | +1,613 | -$1.14M | EDGAR |
| 2024-11-01 | LLY | Gift (G) | −4,302 | $0 | EDGAR |
| 2024-02-14 | LLY | Grant (A) | +2,369 | $1.75M | EDGAR |
| 2024-02-02 | LLY | Mixed | +1,933 | -$1.09M | EDGAR |
| 2023-02-21 | LLY | Mixed | +1,471 | -$440.2K | EDGAR |
| 2023-02-14 | LLY | Grant (A) | +2,407 | $830.7K | EDGAR |